home > pmps > winter 2002 > the environmental impact of metered dose inhalers
Pharmaceutical Manufacturing and Packing Sourcer
The Environmental Impact of Metered Dose Inhalers
Asthma and chronic obstructive pulmonary disease (COPD) are chronic lung diseases and are among the leading causes of morbidity and mortality in the Western world. Asthma is a reversible narrowing of the airways, combined with a chronic inflammation. For reasons largely unknown, the incidence of asthma is rapidly rising. The number of patients increases annually, and today approximately five per cent of the population of the US and Europe suffer from this disease (1-4).
COPD is a chronic inflammation and destruction of the airways. There is a progressive, non-reversible loss of lung function which will eventually lead to invalidity and death. COPD usually occurs in elderly people, of which most are smokers or former smokers (5).
Read full article from PDF >>
Rate this article You must be a member of the site to make a vote.
There are no comments in regards to this article.
You must be a member of the site to make a comment.
By Cees Winnips MD, Director of Business Development at SkyePharma AG
Cornelis 'Cees' Winnips is educated and trained as a physician and began his career in the pharmaceutical industry in 1989 with Ciba-Geigy in the Netherlands. After a short period in the medical department, he moved to the commercial side and worked as Group Product Manager.
In 1993, he relocated to Austria to head the marketing department of Ciba Austria. In 1995, he moved to the Ciba/Novartis head office in Basel, Switzerland as Manager of Business Development, and subsequently became International Product Manager for the respiratory franchise. In 1998, he joined SkyePharma as Director of Business Development.
Cees Winnips
LivaNova to Present Scientific Data on VNS Therapy for Difficult-to-Treat Depression at 4th International Brain Stimulation Conference
LivaNova PLC, a market-leading medical technology and innovation company, today announced its participation in the 4th International Brain Stimulation Conference, taking place December 6 - 9 in Charleston, S.C.
Changing Structural Landscape for Comparator Drug Supply
ADAllen Pharma
TransCelerate Biopharma is focused on advancing innovation in R&D, identifying and solving common R&D challenges and further improving patient safety, with the goal of delivering more high quality medicines to patients. In 2013, they announced its Clinical Trial Comparator Network initiative to show a mutual commitment to offer secure and rapid supply of comparator drug products. The aim of this article is to unpack the section on 'Comparator Drugs' and analyse the rationale for attempting to achieve their objectives.
All white papers >>